Condition

Small Lymphocytic Lymphoma (SLL) clinical trials and research

• 11Clinical trials
• 13Countries

Newest Small Lymphocytic Lymphoma (SLL) clinical trials

All recruiting trials (11)

• Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

  This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

  Recruiting European Research Initiative on CLL · Milan · NCT07774390

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy

  NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.

  Recruiting at 43 sites Phase 2 Nurix Therapeutics, Inc. · Phoenix, Arizona and 42 other locations · NCT07221500

• Quality of life and symptom changes over two years in adults with CLL or SLL starting targeted therapy

  This study will see how quality of life, fatigue, and symptoms change over two years for adults with CLL or SLL who start treatment with a BTK inhibitor versus a BCL2 inhibitor.

  Recruiting H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07030400

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• Zanubrutinib, obinutuzumab, and sonrotoclax for newly diagnosed CLL or SLL

  This trial tests whether the three‑drug combination of zanubrutinib, obinutuzumab, and sonrotoclax can produce undetectable measurable residual disease (uMRD) in people with previously untreated CLL or SLL.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06849713

• Long-term safety of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788639

• Combining anti-CD19 CAR T-cells with Lenalidomide in relapsed/refractory CLL/SLL

  This trial tests whether giving Lenalidomide together with anti-CD19 CAR T-cell therapy is safe and can help people with relapsed or refractory CLL or SLL who have been on ibrutinib.

  Recruiting Phase 1/2 Vitebsk Regional Clinical Cancer Centre · Vitebsk, Select A State · NCT06762431

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

Related topics

Quick answers

How many Small Lymphocytic Lymphoma (SLL) clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in United States (9 trials), Italy (4 trials), Poland (3 trials), United Kingdom (3 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 2, Early Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →